sunvozertinib + anlotinib

Sunvozertinib + anlotinib is a combination therapy under investigation for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR-sensitive mutations and co-mutations. Sunvozertinib is a small molecule inhibitor targeting the epidermal growth factor receptor (EGFR), including uncommon mutations such as exon 20 insertions. Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits angiogenesis and tumor proliferation by targeting receptors such as VEGFR, FGFR, PDGFR, and c-Kit. The combination aims to provide synergistic antitumor activity by simultaneously blocking EGFR-driven tumor growth and angiogenesis pathways. This regimen is being evaluated primarily in advanced or metastatic NSCLC as first-line therapy for patients with specific genetic alterations[1][2][6][7].

Brand names

ShuwozheFukewei

Other names

third-generation EGFR-TKI + anlotinibsunvozertinib plus anlotinib